Effects of gastric bypass on @entity19183 expression in the liver and pancreas of @entity6 XXXX .

@entity6 @entity15212 @entity19183 @entity35 @entity3918 @entity413
AIM: To explore the mechanism by which gastric bypass surgery (GBS) @entity6 ( @entity6 ) by investigating whether @entity19183 (a transcription factor that plays a crucial role in the regulation of glycolipid metabolism) expression is altered in the liver and pancreatic islet cells in a @entity35 model of GBS-treated @entity6 . METHODS: @entity35 were randomly divided into four groups (n   =   10 @entity35 each): @entity6 @entity35 treated by GBS ( @entity3918   +   GBS), @entity6 @entity35 subjected to sham operation ( @entity3918   +   sham), normal control @entity35 (control), and @entity6 @entity35 without surgery ( @entity3918 ). Fasting levels of blood @entity413 (BG), insulin, and glucagon-like peptide-1 ( @entity15212 ) were measured in all groups before and 4, 8, 16, and 24 weeks after operation. @entity35 were killed 24 weeks after surgery. Liver and pancreas expressions of @entity19183 were investigated by immunohistochemistry and Western blotting analyses. RESULTS: In the @entity3918   +   GBS group, fasting BG before and 24 weeks after surgery decreased from 20.2        2.1 to 7.7        1.1   mmol/L, respectively; fasting insulin showed no change (2.9        0.1 and 3.0        0.1   mU/L, respectively); and fasting @entity15212 increased from 8.7        0.9 to 23.5        0.2 pmol/L, respectively. Fasting BG levels after surgery in the @entity3918   +   GBS group were significantly lower than those in the @entity3918   +   sham and @entity3918 groups. @entity19183 expression levels in the liver and pancreatic islets of the @entity3918   +   GBS group were reduced compared to those in the @entity3918   +   sham and @entity3918 groups. @entity19183 in the pancreatic b-cells was expressed mainly in the cytoplasm. CONCLUSIONS: Gastric bypass may improve @entity6 by changing @entity19183 expression in the liver and pancreatic islet cells.
